title: Hepatitis C in European prisons: a call for an evidence-informed response.
abstract: Globally, over 10 million people are held in prisons and other places of detention at any given time. People who inject drugs (PWID) comprise 10-48% of male and 30-60% of female prisoners. The spread of hepatitis C in prisons is clearly driven by injection drug use, with many infected prisoners unaware of their infection status. Risk behaviour for acquisition of hepatitis C via common use of injecting equipment is widespread in many prison settings. In custodial settings, effective and efficient prevention models applied in the community are very rarely implemented. Only approximately 60 out of more than 10,000 prisons worldwide provide needle exchange. Thus, HCV prevention is almost exclusively limited to verbal advice, leaflets and other measures directed to cognitive behavioural change. Although the outcome of HCV antiviral treatment is comparable to non-substance users and substance users out of prison, the uptake for antiviral treatment is extremely low. Based on a literature review to assess the spread of hepatitis C among prisoners and to learn more about the impact for the prison system, recommendations regarding hepatitis C prevention, screening and treatment in prisons have been formulated in this article.
authors.forename: Amber
authors.initials: A
authors.lastname: Arain
authors.forename: Geert
authors.initials: G
authors.lastname: Robaeys
authors.forename: Heino
authors.initials: H
authors.lastname: Stöver
mesh_terms: D005060:Europe / Q000453:epidemiology; D055317:Evidence-Based Practice; D006297:Health Services Accessibility; D006526:Hepatitis C / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission; D006801:Humans; D015995:Prevalence; D011329:Prisoners; D011330:Prisons; D012309:Risk-Taking; D015819:Substance Abuse, Intravenous / Q000150:complications* / Q000453:epidemiology